CIMAvax-EGF Plus KRAS Inhibitor for Advanced Lung Cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two treatments—CIMAvax-EGF (a cancer vaccine) and a KRAS G12C inhibitor (a targeted drug)—for advanced lung cancer with a specific genetic mutation. The goal is to see if adding the vaccine helps the standard KRAS inhibitor work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Advanced non-small cell lung cancer confirmed by tissue or cell sample
- Genetic test showing KRAS G12C mutation in your cancer
- Eligible to receive standard KRAS G12C inhibitor treatment
- Good enough overall health (ECOG performance status ≤ 2: able to care for yourself with minimal help)
- Expected to live at least 6 months
- Blood counts, kidney function, and liver function in acceptable ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
This Phase 1 study tests a KRAS-targeted vaccine combined with chemo and immunotherapy (nivolumab and ipilimumab) for people with advanced non-small cell lung cancer. It aims to help the immune system recognize and fight tumors with specific KRAS mutations, and to see if the treatment is safe and effective enough to study further.
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
This trial tests a new drug (HS-10370) combined with other cancer treatments for people with advanced lung cancer that has a specific mutation called KRAS G12C. It is for those who have not yet received systemic therapy for their advanced disease.
This trial tests a new drug called GFH375, either alone or combined with other treatments, for advanced non-small cell lung cancer that has a specific KRAS G12D mutation. The goal is to see if this targeted approach can slow or shrink your cancer better than standard treatments.
This trial tests a combination of two drugs (Glecirasib and Ivonescimab) as the first treatment for people with non-small cell lung cancer that has a specific mutation called KRAS G12C and has spread or can't be removed by surgery. The goal is to see if this combination helps shrink tumors or slow the cancer down.
Hear when a new Advanced Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.